Plain-language · Issue 4 · 2026-10-15
Mental Health Safety Signal for CFTR Modulators: Evidence from Drug Reporting Databases Calls for Structured Monitoring
Editorially reviewed research summaries, context, and limitations.
Diane A Merino, Samuel D Cohen, Nouha Ben Othman, et al.
Summary: Researchers analyzed reports of psychiatric side effects — including sleep problems, mood changes, and suicidal thoughts — that had been submitted by healthcare professionals and patients to two large drug safety databases: France's national pharmacovigilance database (116 cases) and VigiBase, a global database maintained by the World Health Organization (3,407 cases). Reports covered the years 2012 to 2024 and focused on CFTR modulators, mainly ETI. Using a standard method for detecting whether a particular drug is associated with more reports of a certain problem than would be expected by chance, the researchers found that mental health events were over-represented with ETI compared with other drugs in the database. Sleep problems were the most common concern in children; mood disturbances and reports related to suicidality were more common in teenagers. No completed suicides were reported; six suicide attempts were identified in the French database.
Why it matters: Because ETI is now used by a very large number of people with CF, even a rare side effect could affect many people. Mental health concerns had been raised informally before; this analysis is one of the more systematic efforts to look at psychiatric reports across a large dataset and to break down findings by age group. If a real link between ETI and mental health events exists — particularly in children and teenagers — it would have direct implications for how patients and families are counseled when starting the medicine and how they are monitored over time.
What to keep in mind: This type of analysis — looking at voluntary reports submitted to safety databases — is designed to generate signals and hypotheses, not to prove that a medicine causes a problem. There is no way to know how many people are actually taking the medicine and not reporting problems, so it is impossible to calculate a true rate of side effects. Doctors and patients may be more likely to report mental health events for ETI precisely because the question has been raised publicly — a known bias in safety reporting systems. Critically, people with CF already experience significantly higher rates of anxiety and depression than the general population, simply because of what it means to live with a serious illness. It is also possible that dramatic improvements in physical health from ETI allow people to notice or acknowledge mental health difficulties that were previously overshadowed by physical symptoms. This evidence is not a reason to change prescribing, but it is a reasonable basis for structured, routine mental health check-ins as part of CF care — and for properly designed studies with appropriate comparison groups to determine whether a real causal link exists.
Relevance: Cystic Fibrosis
Source: https://pubmed.ncbi.nlm.nih.gov/42707002/
---